Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Executive Summary
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
You may also be interested in...
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Antios Says Its Novel Hepatitis B Mechanism Can Help Toward Functional Cure
First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.
Finance Watch: New Private Funding Available Across The Spectrum For Biopharma Firms
Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement.